On-demand education
WHO 2022 Classification of Male Genitourinary Tract tumor: What is relevant? Novelties for the practicing urologist?
PARP Inhibitor in Prostate Cancer. Part III
Prof. Nicolas Mottet about the changes in the 2022 guidelines for prostate cancer - Part 2
Prof. Nicolas Mottet about the changes in the 2022 guidelines for prostate cancer - Part 1
Advanced Prostate Cancer – Non-Metastatic Hormone-Sensitive Prostate Cancer (nmHSPC)
PARP inhibitors in prostate cancer. Part 2
Paradigm shifts in metastatic hormone sensitive prostate cancer (mHSPC): Recent treatment developments
Management of Non-metastatic Castration Resistant Prostate Cancer (nmCRPC): Putting current evidence into practice
Artificial intelligence: The role for research and patient treatment
UROwebinar: PARP inhibitors in prostate cancer. Part 1
Identification and management of patients with nmCRPC
Future directions in PCa management
Prostate cancer: Aftercare should not be an afterthought
From clinical trial (ARAMIS, PROSPER, SPARTAN) to Real life. How to identify nmCRPC patient that can benefit from 2nd Gen ARIs?
Prof. Nicolas Mottet shares the new guideline recommendations for prostate cancer - Part 2